Wednesday, August 08, 2007


ScienceDirect - Ophthalmology : Intravitreal Bevacizumab for Treatment of Uveitic Macular Edema

This study concludes:

These results suggest that a single intravitreal injection of bevacizumab is well tolerated and is associated with short-term improvement in VA and decreased OCT retinal thickness in a considerable proportion of patients with uveitic CME resistant to conventional therapy. Further evaluation of intravitreal bevacizumab for uveitic CME in controlled randomized studies is warranted.

No comments:

Post a Comment

Leave a Comment or Question: